Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veltuzumab and 90Y-Epratuzumab in Aggressive NHL
NCT01101581Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- May 2010
- Primary completion
- Dec 2016
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of veltuzumab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), sponsored by Gilead Sciences. Planned start May 2010; status: withdrawn.
02
Drugs
veltuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01101581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01101581.